Price List Yorvipath - Osteoporosis Agents - PTH Analogs.xlsx
XLSX spreadsheet 46 KB Posted
- Solicitation number
- HT9402-24-Q-9404
- Issued by
-
Defense Health Agency
About this file
This document is a request for quotation (RFQ) issued by the Department of Defense (DoD) for the DoD Uniform Formulary (UF) Blanket Purchase Agreement (BPA) and Uniform Formulary Additional Discount Program (UF ADP) related to newly approved pharmaceutical agents in several drug classes, including Osteoporosis Agents - PTH Analogs.
The RFQ states that the DoD Pharmacy and Therapeutics (P&T) Committee will review the newly approved drugs at its November 2024 meeting. Manufacturers are required to submit quotes by October 16, 2024, and a pre-quotation teleconference will be held on October 2, 2024. The RFQ includes detailed pricing templates for the UF BPA and UF ADP, with instructions for manufacturers to provide their pricing information. The Defense Health Agency may award UF BPA and UF ADP agreements based on the P&T Committee's formulary decisions. The RFQ provides background on the DoD's legal requirement to establish an integrated pharmacy benefits program and the process for considering the clinical and cost-effectiveness of drugs for the UF.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List - Aqneursa - Neurological Agents Misc - NA.xlsx | XLSX spreadsheet | |
| Amendment 0001.pdf | ||
| Price List - Cobenfy - Antipsychotic Agents - Atypical.xlsx | XLSX spreadsheet | |
| Price List Onyda XR - ADHD Agents - Non-Stimulants.xlsx | XLSX spreadsheet | |
| RFQ HT9402-24-Q-9404 NAD.pdf | ||
| Price Appendix FAQ NAD.pdf | ||
| Price List Lazcluze - Oncological Agents - Multiple.xlsx | XLSX spreadsheet | |
| Price List Ebglyss - ATOPY - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List Clobetasol Propionate - Ophthalmic - Corticosteroids.xlsx | XLSX spreadsheet | |
| Price List Tryvio - Antihypertensive Agents - Endothelin Receptor Antagonists.xlsx | XLSX spreadsheet | |
| Price List Femlyv - Contraceptive Agents - Multiple.xlsx | XLSX spreadsheet |
Show all 12
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the November 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 |
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering - a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 or 365 days (as determined by the P&T Committee) in order to be excluded from the prior authorization process. Agents designated for Non-Formulary will be designated non step-preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 181OAMIN0UFAS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 181OAMIN0NFAS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the November 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 |
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering - a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 or 365 days (as determined by the P&T Committee) in order to be excluded from the prior authorization process. Agents designated for Non-Formulary will be designated non step-preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | |||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the November 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 |
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering - a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 or 365 days (as determined by the P&T Committee) in order to be excluded from the prior authorization process. Agents designated for Non-Formulary will be designated non step-preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | OSTEOPOROSIS AGENTS | P&T Committee Meeting: | November 6-7, 2024 | ||
| DOD Uniform Formulary Subclass: | PTH ANALOGS | Quotes due: | October 16, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 181OAMIN0T2AS1M | Tier 2 | 1 or more | |
| 181OAMIN0T3AS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .